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Abstract 
The Federal False Claims Act (FCA) is a law that enforces liability on companies (or persons) who 
defraud government programs. Its original purpose was to combat fraud against the United States Army 
during the Civil War. Under the original FCA private citizens could file a lawsuit on behalf of the 
government and receive a percentage of the recovery. 
The False Claims Act has been somewhat effective in combating fraudulent claims by pharmaceutical 
manufacturers. According to the Department of Justice (DOJ) website over $19 billion has been 
collected from the pharmaceutical companies for various violations of the FCA including billing, 
marketing and pricing schemes. 
Our research focused on all cases involving pharmaceutical manufacturers through False Claims Act 
(FCA) violations, specifically the Off-Label Marketing of Drugs. There were 22 cases in the eight years 
that our research covered. The total amount collected in the eight years was over $14.1 billion (Table). 
This was only those cases related to Off-Label Marketing. One company, Pfizer Corp., was involved in 4 
of the 22 cases totaling $3,448 million over a five-year period. Johnson & Johnson Corp. settled 3 cases 
for a total of $2,299 million. 
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1. Introduction 
The Federal False Claims Act (FCA) is a law that enforces liability on companies (or persons) who 
defraud government programs. The FCA is also known as “Lincoln Law” due to the fact that it was our 
16th President who signed this law in 1863. Its original purpose was to combat fraud against the United 
States Army during the Civil War. Under the original FCA private citizens could file a lawsuit on behalf 
of the government and receive a percentage of the recovery. This is known as “qui tam”, referring to 
the Latin expression “qui tam pro domino rage quam pro se ipso in have parte sequitur” which means, 
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“who sues on behalf of the King as well as for himself”. This was part of the FCA legislation to 
encourage citizens to report wrongdoing against the government (Note 1).  
Over the last 150 years, Congress has amended the FCA on three occasions. In 1986, special incentives 
for whistle blowing insiders were added. Up until the 1990s, the FCA had mainly been used against 
defense contractors. Health care fraud then became an emphasis. This led to the amendment of 2009, 
the “Fraud Enforcement Recovery Act”. The 2010 changes were specific to health care under the 
“Patient Protection and Affordable Care Act”.  
The False Claims Act has been somewhat effective in combating fraudulent claims by pharmaceutical 
manufacturers. With the whistleblower provision being implemented in 2009, this has increased the 
cases being brought under the FCA. According to the Department of Justice (DOJ) website over $19 
billion has been collected from the pharmaceutical companies for various violations of the FCA 
including billing, marketing and pricing schemes (Note 2). It is believed, however, that this is simply 
the insignificant portion of something much, much bigger. Some of the more common schemes that the 
drug companies have frequently utilized that may violate the FCA include: 
-Off-label Marketing of Drugs: the use of pharmaceutical drugs for unapproved purposes, dosages, ages, 
etc. Pharmaceuticals in the United States are highly regulated by the Food and Drug Administration 
(FDA). The drugs must be rigorously tested before approval and the FDA determines exactly which 
medical conditions, ages, and dosages the drug may be used to treat. Drug companies that promote 
their drugs to physicians for an off-label or an unapproved use are in violation of federal law (Note 3). 
-Illegal Kickbacks: a common scheme that the pharmaceutical companies have been found guilty of is 
providing payments or other financial incentives to healthcare providers in order to persuade them to 
prescribe their drugs to patients. Also, kickbacks have been known to be paid to the insurance 
companies in order to have their drugs listed as those “preferred” to be prescribed to the insurance 
coverage. 
-Inflated Pricing of Pharmaceuticals: one of the most common schemes used by pharmaceutical 
companies is inflating the prices of their drugs, or reporting to the government what the average price 
for which the drug wholesalers sell the specific drugs to their customers. By reporting a higher average 
price, this increases how much the Medicare and Medicaid programs must pay for those particular 
drugs (Note 4). 
 
2. Method 
Our research focused on all cases involving pharmaceutical manufacturers through False Claims Act 
(FCA) violations, specifically the Off-Label Marketing of Drugs. This law allows for private citizens to 
file antifraud actions on behalf of the government and this imposes liability of up to triple damages 
along with civil penalties for each claim, with the citizens receiving a percentage of the reclamation. 
We used meta-analysis to gather information from previous research. We also compiled our own data 
on the total settlement as well as the amount received by the qui tam relators. Data was collected from 
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Lexis/Nexis and Department of Justice websites. Financial recoveries of less than $5 million were 
excluded. 
 
3. Result 
There were 22 cases in the eight years that our research covered. The total amount collected in the eight 
years was over $14.1 billion (Table 1). This was only those cases related to Off-label marketing. One 
company, Pfizer Corp., was involved in 4 of the 22 cases totaling $3,448 million over a five-year period. 
Johnson & Johnson Corp. settled 3 cases for a total of $2,299 million.  
Although only involved in one of the 22 cases we discovered, the largest healthcare fraud settlement in 
United States history is the $3 billion paid out by Glaxo Smith Kline (GSK). They settled the suit when 
they pled guilty to the off-label marketing of two different drugs for uses that had they had not been 
approved. The pharmaceutical giant admitted that they had held certain information back from the 
Federal Drug Administration (FDA) and they had made unsupported claims over certain drugs. Plus, 
GSK admitted to paying kickbacks to doctors to prescribe and promote their drugs for the off-label 
purposes. The settlement covered both criminal and civil fines with the federal and state governments. 
GlaxoSmithKline paid their $3 billion fine out of their cash reserves immediately upon learning of their 
penalty (Note 5). From 1991 through 2015, GSK paid financial penalties of $7.9 billion to federal and 
state governments. This is double what any other pharmaceutical company has paid. 
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Company Headquarters Year Total  Recovered   Amount Recovered by 
Qui  Tam Fi lers   Violation
El i  Li l ly and Company Indianapol i s , Indiana, 
United States 2009 1,400$                  438$                                   Off‐label  promotion
Pfizer
New York, New York, 
United States 2009 2,900$                  102$                                   Off‐label  promotion
Pfizer (Alpharma) Bris tol , Tennessee, United 
States
2010 42.5$                    5.33$                                  Off‐label  promotion
AstraZeneca Cambridge, England 2010 520$                     N/A Off‐label  promotion
Johnson & Johnson ( Ortho‐
McNei l  Pharmaceutica l  and 
Ortho‐McNei l ‐Janssen)
Rari tan, New Jersey, 
United States 2010 81$                       9$                                       Off‐label  promotion
Novarti s  International  AG Basel , Switzerland 2010 72.5$                    7.8$                                    Off‐label  promotion
Al lergan, PLC
Dubl in, Ireland, and 
Pars ippany‐Troy Hi l l s , New 
Jersey, United States .
2010 600$                     37.8$                                  Off‐label  promotion
Novarti s  International  AG Basel , Switzerland 2010 422.5$                  25$                                     Off‐label  promotion/kickbacks
Forest Laboratories , Inc. New York, New York, 
United States 2010 313$                     14$                                    
Off‐label  
promotion/dis tribution of an 
unapproved drug (Levothroid)
Élan Corporation, PLC (acquired 
by Perrigo Co. in 2013) Dubl in, Ireland 2010 214.5$                  10$                                     Off‐label  promotion
Abbott Laboratories  (Kos  
Pharmaceutica ls )
Lake  Bluff, I l l inois , United 
States
2010 41$                       6.4$                                    Off‐label  promotion/kickbacks
UCB Brussels , Belgium 2011 34$                       2.8$                                    Off‐label  promotion
Pfizer
New York, New York, 
United States 2011 14.5$                    3.3$                                    Off‐label  promotion
Abbott Laboratories Lake  Bluff, I l l inois , United 
States
2012 1,500$                  84$                                     Off‐label  promotion
GlaxoSmithKl ine Brentford, United Kingdom 2012 3,000$                  34$                                     Off‐label  promotion/kickbacks Paxi l , wel lbutrin, avandia  and other drugs .
Pfi zer (Wyeth Pharmaceutica ls ) New York, New York, 
United States 2013 490.9$                  N/A Off‐label  promotion
Johnson & Johnson New Brunswick, New 
Jersey, United States 2013 2,200$                  167.7$                                Off‐label  promotion/kickbacks
CareFus ion
San Diego, Cal i fornia , 
United States 2014 40.1$                    3.26$                                  Off‐label  promotion/kickbacks
Endo Internationa l , PLC (Endo 
Pharmaceutica ls )
Dubl in, Ireland, and 
Malvern, Pennsylvania , 
United States
2014 192.7$                  N/A Off‐label  promotion/kickbacks
Johnson & Johnson (Acclarent) New Brunswick, New 
Jersey, United States 2016 18$                       N/A
Off‐label  
promotion/misbranding
BTG PLC (Biocompatibles  Inc.) London, United Kingdom 2016 36$                       N/A Off‐label  
promotion/misbranding
Bris tol ‐Myers  Squibb Company New York, New York, 
United States 2016 19.5$                    N/A
Off‐label  
promotion/misbranding
Totals: 14,152.70$           950.39$                             
14.1 bi l l ion 950 mil l ion
Al l  $ amounts  in Mil l ions
Zyprexa  (antipsychotic, for schizophrenia  and 
bipolar disoder)
Bextra  (NSAID), Geodon (anti ‐psychotic for 
Schi tzophrenia/acute  mania/mixed bipolar 
s tates ), Zyvox (antibiotic), and Lyrica  (for 
epi lepsy, neuropathic pa in, fibromia lgia , and 
genera l  anxiety disorder)
Kadian (extended‐release  morphine)
Settled Federal  False  Cla ims  Act Cases  Involving Pharmaceutica l  Product Manufacturers  (2009‐2016)
Seroquel  (anti ‐psychotic for schizophrenia , 
bipolar disorder, and major depress ive  
disorder)
Topamax (anticonvulsant/antiepi lepsy)
Product (type/FDA approved usage)
Botox (neurotoxic protein, for headaches , neck 
pa in, cervica l  dystonia , and axi l la ry 
hyperhidros is )
Tobi  (antibiotic)
Tri lepta l  (anticonvulsant, for treatment of 
partia l  seizures  associated with epi lepsy)
Levothroid (thyroid hormone), Celexa  
(SSRI/antidepressant, for major depress ion), 
and Lexapro (SSRI/antidepressant, for major 
depress ion and genera l i zed anxiety disorder)
Zonegran (anticonvulsant, for Parkinson's  
disease, partia l ‐onset seizures , Lennox‐
Gastaut syndrome, and other seizures )
Advicor (Niacin & Lovastatin mix, for 
dys l ipidemia  and Niaspan (Niacin, for 
cardiovascular disease, etc.)
Lidoderm (Lidocaine/local  anaesthetic, for 
numbing)
Sinus  Spacer Product (dis tributed as  a  drug 
del ivery method after FDA denia l  to expand 
the  product's  approved usages)
LC Bead (embol ization device, to be  inserted 
into blood vessels  to restrict bloodflow to 
tumors )
Abi l i fy (antipsychotic, for schizophrenia  and 
bipolar disorder)
Keppra  (For epi lepsy)
Detrol  (antimuscarinic, for urinary 
incontinence)
Depakote  (For epi lepsy, bipolar disorder, and 
prevention of migra ines)
Rapamune  (immunosupressant, for coronary 
s tents  and prevention of organ transplant 
rejections)
Risperdal  (antipsychotic, for schizophrenia , 
bipolar disorder, and i rri tabi l i ty in Autis tic 
individuals ), Invega  (dopamine  
antagonis t/antipsychotic, for bipolar disorder, 
schizophrenia , and schizoacffective  disorder) 
and Natrecor (cardiovascular amino acid 
recombinant, for types  of congestive  heart 
fa i lure)
ChloraPrep (surgica l  dis infectant & antiseptic, 
for skin & surgica l  ins trument 
dis infection/steri l i zation before  surgica l  
appl ication)
 
Figure 1. Settled False Claims Act Cases Involving Pharmaceutical Product Manufacturers 
(2009-2016) 
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The United States pharmaceutical industry was worth an estimated $446 billion in 2016. The United 
States holds over 45 percent of the world’s pharmaceutical marketplace. Six out of the top ten drug 
companies in the world are from the U.S. It is said to be the “world’s most important national market” 
(Note 6). The largest pharmaceutical company in the United States in 2015 was Pfizer Corporation. 
Their revenue in 2015 was almost $49 billion (in November of 2015 Pfizer merged with an Irish 
company and moved their headquarters to Ireland, thus lowering their tax rate by almost half) (Note 7). 
 
4. Discussion 
Since 1996, $19 billion has been collected from pharmaceutical companies for various pricing, billing 
and marketing schemes that are in violation of the Federal and State False Claims Acts. So, in relation 
to the 2008 bank bailout, the American banks were said to be “too big to fail”. But, the bank bailout of 
2008 was only $700 billion (Note 8). The pharmaceutical companies just keep getting bought up and 
are currently in the “too big to fail” category in the United States. Once one starts to go down, it’s just 
bought up by another: similar to how banks were in 2008. But, remember how the bank collapse ruined 
the United States economy. Stocks plummeted, mortgages became too expensive, peoples’ money 
became worthless. Think of how a failure in the prescription medication industry would affect the 
country. People already cannot afford their medications, which they desperately need. In 2015, Martin 
Shkreli raised the price of a malaria medication by a factor of 56, making it almost $700/pill. When 
pricing fraud like this occurs, it’s not a matter of just the economy. People die when they cannot afford 
their medication. It is becoming all too common for people to have to choose between buying food or 
buying their medication.  
As a fraudulent industry with sales above $1 trillion in 2014 ($450 billion in the U.S. alone), the 
pharmaceutical industry is notorious for hiring former government employees in an effort to farm their 
political connections to gain political standing. The trade group PhRMA actually has 50+ former and 
current employees who used to work in the government. These include 36 former Congress members, 
13 who used to work for federal agencies, 12 who were a part of a congressional committee, 2 formerly 
worked for the White House, and one who was employed by the court system (Note 9). These political 
connections give the pharmaceutical industry a significant advantage over other industries. 
Pharmaceutical companies are already protected from free-market competition. That’s a perk that only 
U.S. pharmaceutical companies have (as well as marketing directly to doctors and consumers, those 
methods aren’t typical in European countries). 
Pharmaceutical companies need to be held to a higher standard in the United States. They go widely 
unregulated and while it seems as though they’re bleeding money from all the settlements they expense 
out, the amount of fraud inherent to keep the companies alive is blatantly apparent and needs to be 
cracked down on before it becomes paralleled with the 2008 housing crisis. The United States produces 
and purchases more than 47% of the world’s pharmaceuticals, which is far more than any other country 
on the planet. The fact that they are not subjected to free-market competition only makes it easier for 
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the bad guys to get richer while everyone else gets sicker (Note 10). 
The high costs of pharmaceuticals in the United States are not only the fault of the companies, however. 
Just recently, July 2017, the Attorney General announced that charges were being filed against 412 
doctors, nurses and pharmacists in what he called, “the largest health care fraud enforcement operation 
in U.S. history” (Johnson). In this particular case, one doctor has been accused of writing more than 
12,000 prescriptions for opioids. That is the equivalent to more than 2 million illegal doses. Other 
doctors have been accused of writing more prescriptions for opioids than an entire hospital would 
normally write. This inflated demand, leads to inflated costs. Abuse of the expensive painkillers can 
then lead addicts to cheaper alternatives, mainly heroin. In this same case, a group of six Michigan 
doctors are accused of providing patients with unnecessary opioid prescriptions and then billing 
Medicare for $164 million. Some of those same prescriptions ended up being resold on the streets to 
addicts (Note 11). 
 
5. Conclusion 
Our analysis has limitations, principally the absence of other FCA violations other than off-label 
marketing. Despite this, our analysis emphasizes that many of the larger pharmaceutical companies 
have been implicated in health care fraud cases, sometimes more than once. With the growth of the 
health care industry, investigations into the manufacturers of pharmaceutical drugs will continue to 
result in significant recoveries. Our research also raises concerns that despite these sizeable recoveries, 
industry wide changes are much needed (Note 12). 
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